Abstract | BACKGROUND: METHODOLOGY/PRINCIPAL FINDINGS: This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA(1c) (-0.10+/-0.65 % vs. 0.09+/-0.52 %, P = 0.001) compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites ( enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2+/-18.1 vs. 1.2+/-2.4 microg/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. CONCLUSIONS/SIGNIFICANCE: TRIAL REGISTRATION: ClinicalTrials.gov NCT00363233.
|
Authors | An Pan, Jianqin Sun, Yanqiu Chen, Xingwang Ye, Huaixing Li, Zhijie Yu, Yanfang Wang, Wenjia Gu, Xinyi Zhang, Xiafei Chen, Wendy Demark-Wahnefried, Yong Liu, Xu Lin |
Journal | PloS one
(PLoS One)
Vol. 2
Issue 11
Pg. e1148
(Nov 07 2007)
ISSN: 1932-6203 [Electronic] United States |
PMID | 17987126
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Aged
- Cross-Over Studies
- Diabetes Mellitus, Type 2
(diet therapy)
- Double-Blind Method
- Female
- Flax
(chemistry)
- Humans
- Lignans
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Placebos
- Treatment Outcome
|